Treatment with lenalidomide induces long-lasting responses
Lenalidomide can produce a sustained increase in immunoglobulin levels and a sustained normalization in circulating T cells
We evaluated the long-term outcomes of 60 patients with chronic lymphocytic leukemia (CLL) treated with lenalidomide as initial therapy. At a median follow-up of 4 years, median time to treatment failure has not been reached, overall survival is 82%. Thirty-five (58%) patients had a response lasting more than 36 months (long-term responders, LTRs). Best responses in LTRs consisted of 25 (71%) complete remissions and 10 (29%) partial remissions. Beside clinical responses, an increase in immunoglobulin A, G and M levels of greater than 50% from baseline was reported in 61, 45 and 42% of LTRs. Normalization in the percentage of CD4+ and CD8+ cells and T cell numbers was observed in 48, 71 and 99% of LTRs. Compared to the other patients in the study, LTRs had lower baseline plasma levels of beta-2-microglobulin and were more likely to have trisomy 12 and less likely to have deletion 17p. (Trial registered at http://clinicaltrials.gov, ID: NCT00535873)
- Submitted April 5, 2013.
- Accepted June 8, 2013.
- Copyright © 2005 American Society of Hematology